Oncomatryx

Oncomatryx at BIO-EUROPE Spring 2016

por

[vc_row][vc_column][vc_column_text][/vc_column_text][/vc_column][/vc_row][vc_row][vc_column][/vc_column][/vc_row][vc_row][vc_column width=»1/2″][vc_column_text] BIO-EUROPE  Spring 2016. April 4-6, 2016. Stockholm, Sweden. Oral Presentation: “Tumor microenvironment – targeted biopharmaceuticals”. Laureano Simón, PhD If you are also attending Bio-Europe and would like to meet us please fill this form to arrange an appointment.[/vc_column_text][/vc_column][vc_column width=»1/2″][contact-form-7 id=»804″ title=»Meeting at BIO SPRING»][/vc_column][/vc_row]

Ampliación Capital Oncomatryx

por

Publicada en el periódico LA VANGUARDIA 15-12- 2015. Oncomatryx amplía capital para completar la fase preclínica de medicamentos contra el estroma tumoral La empresa vasca Oncomatryx ha finalizado una ronda de ampliación de capital de 4,5 millones de euros con el objetivo de completar los ensayos preclínicos de la «pionera» molécula denominada OMTX, que ha … Leer más

Capital Increase

por

Published by La Vanguardia 2015-12-15. Oncomatryx expands capital to complete the preclinical phase of drugs against tumor stroma The Basque company Oncomatryx has completed a round of capital increase of 4.5 million euros with the aim of completing the preclinical trials of the “pioneer” molecule named OMTX, which has been developed against the tumor stroma, … Leer más

Guerra contra el cáncer desde el stroma: nueva via para el cáncer de páncreas

por

Contra el cáncer desde el stroma: nueva via para el cáncer de páncreas Por Laureano Simon, CEO de Oncomatryx Pancreatic cancer is the fourth most fatal cancer in men and women. Most patients with pancreatic cancer progress to either metastatic or locally advanced disease in the asymptomatic phase. Its prognosis has not improved over the … Leer más

War on cancer stroma: a novel pathway to treat pancreatic cancer

por

War on cancer stroma: a novel pathway to treat pancreatic cancer By Laureano Simon, CEO at Oncomatryx Pancreatic cancer is the fourth most fatal cancer in men and women. Most patients with pancreatic cancer progress to either metastatic or locally advanced disease in the asymptomatic phase. Its prognosis has not improved over the past 20 years; … Leer más

Declaro la guerra al estroma

por

LAUREANO SIMÓN, Oncomatryx CEO, declara la guerra al estroma del cáncer. «We envision a new era where cancer in general and invasive tumors in particular will be beaten with orchestrated combinations of precision drugs that target the epitelial tumor cells, to block tumor growth and drugs that target the tumor microenvironment, to block tumor invasion, angiogenesis, metastasis, immunosupression and … Leer más

World ADC Berlin. 8-10 Febrero 2016

por

6th World ADC Summit. 8th-10th February 2016. Berlin (Germany). ONCOMATRYX will be attending World ADC Berlin. Poster Presentation:  “OMTX705, a powerful stroma-targeting ADC to treat invasive tumors” by Myriam Fabre, PhD. If you are also attending WORLD-ADC and would like to meet us please fill the form below to arrange an appointment.   [contact-form-7 id=»804″ title=»CONGRESS appointment»]

World ADC Berlin

por

6th World ADC Summit. 8th-10th February 2016. Berlin (Germany). ONCOMATRYX will be attending World ADC Berlin. Poster Presentation:  “OMTX705, a powerful stroma-targeting ADC to treat invasive tumors” by Myriam Fabre, PhD. If you are also attending WORLD-ADC and would like to meet us please fill the form below to arrange an appointment. [contact-form-7 id=»804″ title=»CONGRESS appointment»]

El «tumor microenvironment»

por

El «tumor microenvironment»: Un elemento clave al que disparar Novel precision drugs that target the tumor microenvironment are entering the battlefield against cancer. Recent advances in the prevention and treatment of early stages of cancer have achieved significant success. However, little progress has been made in the development of new methods to fight late and invasive stages … Leer más

Tumor microenvironment: A cancer key player to be fired

por

Tumor microenvironment: A cancer key player to be fired Novel precision drugs that target the tumor microenvironment are entering the battlefield against cancer. Recent advances in the prevention and treatment of early stages of cancer have achieved significant success. However, little progress has been made in the development of new methods to fight late and invasive stages … Leer más